Oct. 11, 2017

LEO Science & Tech Hub Announces a Collaboration with Elektrofi for Formulation Technology to Improve Dermatological Drug Delivery

LEO Science & Tech Hub, today announced a collaboration agreement with Elektrofi, a Cambridge-based biotechnology company focused on drug delivery innovations, to explore advanced formulation technology for dermatological drug delivery. “We are excited to announce this collaboration with Elektrofi to explore its innovative Elektroject™ process technology to increase our options in subcutaneous delivery of antibodies” […]

LEO Science & Tech Hub, today announced a collaboration agreement with Elektrofi, a Cambridge-based biotechnology company focused on drug delivery innovations, to explore advanced formulation technology for dermatological drug delivery.

“We are excited to announce this collaboration with Elektrofi to explore its innovative Elektroject™ process technology to increase our options in subcutaneous delivery of antibodies” said Michael Sierra, Ph.D., VP of LEO Science & Tech Hub. “Developing therapeutic solutions that are not only safe and effective but also convenient for patients with skin diseases is critical to improving patient experience and outcomes, which is a goal the Hub strives to achieve.”

Elektrofi leverages a novel therapeutic microparticle suspension system (Elektroject™) to engineer high-concentration, low-viscosity antibody formulations. While many antibody formulations become virtually unusable at high concentrations due to high viscosity, Elektroject™ suspensions result in antibody concentrations that are more than 15x the typically administered concentration without exceeding viscosity limits. This enables healthcare professionals to subcutaneously administer high doses of antibody-based therapies in a relatively small volume within seconds.

“We want to create a paradigm shift in drug delivery to dramatically improve the lives of patients,” said Jason Norris, Co-Founder of Elektrofi. “LEO Science & Tech Hub is a leader in accelerating precision medicine in dermatology, and we are delighted to enter this collaboration which will combine Elektrofi’s work in transforming drug delivery with the Hub’s expertise in dermatology.”

Please read the full press release on the following link.

 

News from the hub

Jul. 2018 11 Hacking Dermatology Selects 5 Finalist Teams for Incubation

Hacking Dermatology is an initiative that aims to bring interdisciplinary teams together to solve the important challenges facing patients with skin disease. It is led and supported by a consortium of academic, non-profit, and industry partners, including Hacking Medicine Institute (HMi), LEO Pharma, Advancing Innovation in Dermatology (AID), MIT Hacking Medicine, and the Lahey Medical […]

Read more
Apr. 2018 12 LEO Science & Tech Hub Enters Collaboration with Dina Katabi MIT, CSAIL to Explore the Use of Radio Signals for Quantification of Itch

LEO Science & Tech Hub, the Boston based R&D unit of LEO Pharma, has entered into a collaboration with Dina Katabi and MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL). Together they will explore the potential of the MIT group’s Emerald system to quantify scratching behavior. The Emerald technology uses the reflection of radio signals to measure human […]

Read more